tiprankstipranks
Trending News
More News >
Kainos Laboratories, Inc. (JP:4556)
:4556
Japanese Market
Advertisement

Kainos Laboratories, Inc. (4556) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4556

Kainos Laboratories, Inc.

(4556)

Rating:84Outperform
Price Target:
¥1,442.00
▲(15.36%Upside)
Kainos Laboratories, Inc. receives a strong overall score due to its excellent financial performance and attractive valuation. The company's robust financial position supports its growth trajectory, while its low P/E ratio and solid dividend yield make it appealing for value and income investors. Technical analysis presents a neutral to slightly bullish outlook, contributing to the overall score.

Kainos Laboratories, Inc. (4556) vs. iShares MSCI Japan ETF (EWJ)

Kainos Laboratories, Inc. Business Overview & Revenue Model

Company DescriptionKainos Laboratories, Inc. (4556) is a Japanese company primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates within the healthcare and biotechnology sectors, focusing on delivering innovative solutions in diagnostics and therapeutics. Kainos Laboratories is committed to advancing medical technology and improving health outcomes through its diverse range of products and services.
How the Company Makes MoneyKainos Laboratories, Inc. generates revenue through the sale of its pharmaceutical products, which include diagnostic reagents and therapeutic drugs. The company invests in research and development to create innovative medical solutions that meet the needs of healthcare providers and patients. Revenue streams are primarily driven by its product sales to hospitals, clinics, and laboratories. Additionally, Kainos Laboratories may engage in strategic partnerships and collaborations with other healthcare organizations and research institutions to expand its market reach and enhance its product offerings. These partnerships could also contribute to revenue through joint ventures or co-development projects.

Kainos Laboratories, Inc. Financial Statement Overview

Summary
Kainos Laboratories, Inc. is performing exceptionally well across all financial verticals. The company shows strong revenue growth and profitability, backed by excellent operational efficiency. Its balance sheet is robust with low leverage and high equity. Cash flow metrics are impressive, demonstrating effective cash management strategies. Overall, Kainos Laboratories is in a stable financial position, supporting its growth trajectory in the medical instruments and supplies industry.
Income Statement
85
Very Positive
Kainos Laboratories has demonstrated consistent revenue growth with a Revenue Growth Rate of 4.93% from 2024 to 2025. The Gross Profit Margin is 49.28% for 2025, indicating strong profitability. The Net Profit Margin has improved to 12.08%, reflecting efficient cost management. EBIT and EBITDA margins are robust at 15.52% and 17.66%, respectively, highlighting the company's operational efficiency.
Balance Sheet
88
Very Positive
The company maintains a strong financial position with a low Debt-to-Equity Ratio of 0.09, indicating conservative leverage. The Equity Ratio is high at 77.12%, showing a strong capital structure. Return on Equity (ROE) is healthy at 9.46%, reflecting effective use of equity capital to generate profits.
Cash Flow
90
Very Positive
Kainos Laboratories exhibits strong cash flow performance with a Free Cash Flow Growth Rate of 78.44% from 2024 to 2025. The Operating Cash Flow to Net Income Ratio is favorable at 1.10. The Free Cash Flow to Net Income Ratio stands at 0.99, indicating efficient conversion of earnings into free cash flow.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue5.31B5.06B4.92B4.61B4.26B
Gross Profit2.61B2.55B2.51B2.41B2.31B
EBITDA936.87M1.05B994.26M924.87M763.42M
Net Income641.02M637.97M568.17M512.33M417.40M
Balance Sheet
Total Assets8.79B8.59B8.12B7.57B6.96B
Cash, Cash Equivalents and Short-Term Investments3.40B3.17B3.02B2.68B2.24B
Total Debt629.49M862.97M941.10M947.61M1.00B
Total Liabilities2.01B2.32B2.45B2.37B2.30B
Stockholders Equity6.78B6.27B5.67B5.20B4.66B
Cash Flow
Free Cash Flow633.30M354.87M536.81M463.19M518.06M
Operating Cash Flow704.78M430.58M544.51M604.36M591.25M
Investing Cash Flow-71.30M-72.83M-10.33M-141.19M-117.16M
Financing Cash Flow-411.04M-203.73M-191.14M-31.25M-194.61M

Kainos Laboratories, Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1250.00
Price Trends
50DMA
1236.24
Negative
100DMA
1216.38
Positive
200DMA
1197.47
Positive
Market Momentum
MACD
-0.83
Negative
RSI
48.56
Neutral
STOCH
76.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Neutral. The current price of 1250 is above the 20-day moving average (MA) of 1232.90, above the 50-day MA of 1236.24, and above the 200-day MA of 1197.47, indicating a neutral trend. The MACD of -0.83 indicates Negative momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 76.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4556.

Kainos Laboratories, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
84
Outperform
¥5.16B8.29
2.56%4.93%-0.26%
76
Outperform
¥5.75B7.36
1.85%8.60%33.64%
72
Outperform
¥127.83B23.42
3.08%5.82%-20.09%
72
Outperform
¥14.38B12.97
3.16%2.58%-53.08%
61
Neutral
¥10.65B120.55
3.90%6.83%
61
Neutral
¥72.90B16.81
2.42%15.55%42.14%
50
Neutral
AU$2.63B2.90-57.47%2.40%36.37%14.48%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4556
Kainos Laboratories, Inc.
1,250.00
81.23
6.95%
JP:7702
JMS Co., Ltd.
435.00
-61.65
-12.41%
JP:7730
Mani, Inc.
1,265.50
-783.82
-38.25%
JP:7743
Seed Co., Ltd.
470.00
-71.18
-13.15%
JP:7979
Shofu Inc.
2,021.00
-304.45
-13.09%
JP:7980
Shigematsu Works Co., Ltd.
815.00
16.78
2.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 27, 2025